EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies

Omar Abdelmotaleb, Antonio Sorrentino, Christiane Neumann, Tanja Fauti, Tina Weinzierl, Anne Freimoser-Grundschober, Claudia Ferrara Koller, Linda Arnold, Sylvia Herter, Matthias E Lauer, Philippe Ringler, Clara Albani und 12 weitere

Antibody Therapeutics · 08.11.2026

DOI: 10.1093/abt/tbag057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 08.11.2026. Verfasst von Omar Abdelmotaleb und 23 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The overall activity of T cell engaging bispecific antibodies (TCBs) is governed by an interplay of various factors including antigen density, binding epitope, affinity, and molecular geometry. Conventional 1+1 IgG-like-TCBs represent the most utilized format amongst approved TCBs and offer prolonged pharmacokinetics via silenced Fc domains. Nevertheless, head-to-tail (HtT) formats, such as the 2+1 TCBs, have gained interest more recently.

Methods

Here, we systematically evaluated HtT configurations, including 1+1 one-armed (OA), 2+1 classical, and 2+1 inverted TCB formats, against standard 1+1 IgG-like TCBs across CEACAM5, FOLR1, MCSP, and CD20 as tumor antigens. Assessments included in vitro functional assays, in vivo humanized mouse models, and biophysical characterization via negative-stain transmission electron microscopy (NS-TEM) and liquid-state atomic force microscopy (AFM).

Results

HtT geometries consistently outperformed standard 1+1 IgG-like TCBs in tumor cell lysis, T-cell activation, and tumor growth inhibition. Biophysical analyses confirmed that the 2+1 inverted format possesses exceptional conformational flexibility, behaving as freely jointed rigid segments. Crucially, by positioning the CD3-binding site internally, the 2+1 inverted format circumvents N-terminal steric restrictions of the tumor antigen binder, preserving high-avidity tumor engagement. Furthermore, in vivo evaluation demonstrated that the HtT configuration remains highly efficacious in combination with standard bivalent CD20 monoclonal antibodies.

Conclusions

The asymmetric inverted configurations of TCBs represent a robust, versatile, and highly combinable platform for next-generation TCB design.

Zitieren

APA

Abdelmotaleb, O., Sorrentino, A., Neumann, C., Fauti, T., Weinzierl, T., Freimoser-Grundschober, A., Koller, C. F., Arnold, L., Herter, S., Lauer, M. E., Ringler, P., Albani, C., Lang, S., Diggelmann, S., Limani, F., Colombetti, S., Sam, J., Puijenbroek, E., Moessner, E., …, & Waldhauer, I. (2026). Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag057

Vancouver

Abdelmotaleb O, Sorrentino A, Neumann C, Fauti T, Weinzierl T, Freimoser-Grundschober A, et al. Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag057

BibTeX
@article{Abdelmotaleb2026,
  author = {Abdelmotaleb, Omar and Sorrentino, Antonio and Neumann, Christiane and Fauti, Tanja and Weinzierl, Tina and Freimoser-Grundschober, Anne and Koller, Claudia Ferrara and Arnold, Linda and Herter, Sylvia and Lauer, Matthias E and Ringler, Philippe and Albani, Clara and Lang, Simone and Diggelmann, Sarah and Limani, Florian and Colombetti, Sara and Sam, Johannes and Puijenbroek, Erwin and Moessner, Ekkehard and Brünker, Peter and Bacac, Marina and Umana, Pablo and Klein, Christian and Waldhauer, Inja},
  title = {Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies},
  journal = {Antibody Therapeutics},
  year = {2026},
  doi = {10.1093/abt/tbag057}
}
Kostenlos starten →